These signs should be checked by a healthcare provider right away
Consequently, choosing anti-hyperglycemic therapies with proven cardiovascular and renal benefits is now a cornerstone of T2DM management [2]
Additional trials expected to report data include: TRIUMPH-1 TRIUMPH-2 TRIUMPH-3 TRIUMPH-5 TRIUMPH-CVOT These studies will evaluate retatrutide in broader obesity populations, diabetes patients, cardiovascular disease populations, and long-term outcomes
Stern, MD, Massachusetts General Hospital, 55 Fruit St, WRN 606, Boston, MA 02114 ([email protected])
While things may be trending in the right direction, the runway for a turnaround wont last forever, said Paul Hattis, senior fellow at the Lown Institute, a nonpartisan health care think tank
Another triple receptor agonist named SAR441255 was later designed and tested in diet-induced obese mice, confirming the initial discoveries reported in 2015 [95]